Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

C. Garufi, C. Nisticò, S. Brienza, A. Vaccaro, A. D'Ottavio, A. R. Zappalà, A. M. Aschelter, E. Terzoli

Research output: Contribution to journalArticlepeer-review


Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients. Patients and methods: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed. Results: The median number of courses per patient was four (range 2-6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5-43.3) which represents 100% of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21%), (95% confidence interval (CI): 0%-43%), two stable disease (14%) and nine progressed (64%). Response lasted five, four and five months respectively. Median survival was 12 months. Conclusions: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluororacil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalAnnals of Oncology
Issue number2
Publication statusPublished - 2001


  • Breast cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study'. Together they form a unique fingerprint.

Cite this